` 2AB (Vaccitech PLC) vs DAX Index Comparison - Alpha Spread

2AB
vs
D
DAX Index

Over the past 12 months, 2AB has underperformed DAX Index, delivering a return of -43% compared to the DAX Index's +15% growth.

Stocks Performance
2AB vs DAX Index

Loading
2AB
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
2AB vs DAX Index

Performance Gap Between 2AB and GDAXI
HIDDEN
Show

Performance By Year
2AB vs DAX Index

Loading
2AB
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Vaccitech PLC vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Vaccitech PLC
Glance View

Market Cap
22.8m EUR
Industry
Biotechnology

Vaccitech Plc operates as a holding company. The company is headquartered in Oxford, Oxfordshire and currently employs 72 full-time employees. The company went IPO on 2021-04-30. The firm is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The firm uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The firm has a pipeline of both clinical and preclinical stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB), VTP-200 for the treatment of human papilloma virus infection (HPV), VTP-850 for the treatment of prostate cancer and VTP-600 for the treatment of non-small cell lung cancer (NSCLC). Its prophylactic programs include VTP-400 for the prevention of herpes zoster (shingles), and VTP-500 for the prevention of the Middle East respiratory syndrome (MERS).

2AB Intrinsic Value
HIDDEN
Show
Back to Top